Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Publication year range
1.
Mult Scler Relat Disord ; 21: 69-70, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29474980

ABSTRACT

Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of congenital abnormalities following exposure to Fingolimod. Here, we report a 34-year-old female, with a 10-year history of MS who had unexpected pregnancy with exposure to generic Fingolimod during the first 7 weeks. The infant was born with dextrocardia, but without any further structural cardiac or other abnormalities.


Subject(s)
Dextrocardia/chemically induced , Fingolimod Hydrochloride/adverse effects , Immunosuppressive Agents/adverse effects , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Pregnancy Complications/drug therapy , Pregnancy Trimester, First , Dextrocardia/diagnostic imaging , Female , Fingolimod Hydrochloride/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Pregnancy , Pregnancy, Unplanned
SELECTION OF CITATIONS
SEARCH DETAIL
...